Skip to content
OpenCapital
Get started

CytomX Therapeutics CTMX Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$10.3MBeat by $5.6M
EPS-$0.10Beat by $0.04
Revenue estimate$4.7M
EPS estimate-$0.14

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$12.4M
EPS estimate-$0.11

Financials

Q1 2026

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$707.53M+87.9%
Enterprise value$681.56M+104%
P/S19.9×+17.2×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%—
Debt / equity0×-0.3×
Current ratio10.4×+8.7×

Versus estimates

Revenue

Q1 2026$10.3MBeat by $5.6M
Q4 2025$661.0KMiss by $6.7MQ3 2025$6.0MMiss by $1.4MQ2 2025$18.7MBeat by $378.0KQ1 2025$50.9MBeat by $15.5MQ4 2024$38.1MBeat by $25.1M

Diluted EPS

Q1 2026-$0.10Beat by $0.04
Q4 2025-$0.22Miss by $0.14Q3 2025-$0.09Miss by $0.04Q2 2025-$0.00Beat by $0.06Q1 2025$0.27Beat by $0.15Q4 2024$0.22Beat by $0.45

Ask the moment CytomX Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did CytomX Therapeutics report Q1 2026 earnings?
CytomX Therapeutics (CTMX) reported Q1 2026 earnings on May 7, 2026 after market close.
What were CytomX Therapeutics's Q1 2026 revenue and EPS?
CytomX Therapeutics reported revenue of $10.3M and eps of $-0.10 for Q1 2026.
Did CytomX Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $4.7M by $5.6M. EPS beat the consensus estimate of $-0.14 by $0.04.
How did CytomX Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 79.9% from $50.9M a year earlier.
Where can I find CytomX Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-211920) and the 10-Q periodic report (0001193125-26-211868) directly on SEC EDGAR. The filing index links above go to sec.gov.